Texas Court Ruling Invalidating ACA Threatens Preexisting Illness Coverage, But It's Not The Final Word, Congress Says

A Texas federal district court judge ruled late on Dec. 14 that all of the Affordable Care Act – including parts mandating coverage of preexisting conditions, the medical device excise tax and reporting by medtech firms of payments made to health-care providers under sunshine provisions – are invalid because the health-care law's individual mandate was struck down by a 2017 tax law. But Congress and legal experts say the ruling will be challenged.

Courthouse Pillars & Stairs

A closely watched court decision by a US District judge for a Texas federal court striking down the constitutionality of the Affordable Care Act would have a sweeping impact on all remnants of the law, including the medical device tax, preexisting conditions coverage and mandatory reporting to the "Open Payments" database – but the ruling may not have staying power, legal experts say.

Even the Trump administration’s Department of Health and Human Services cautioned Monday that the decisionby Judge Reed O’Connor of the US District Court for the Northern District of Texas...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal & IP

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.